Table 4.
Risk factors for CRE acquisition
| Variable | Without CRE | Acquired CRE | p-value | HR | 95% CI interval | p-value |
|---|---|---|---|---|---|---|
| (n = 374) | (n = 44) | |||||
| Demographics | ||||||
| Age | 54 ± 18 | 55 ± 18 | 0.81 | |||
| Male sex | 195 (52%) | 26 (59%) | 0.38 | |||
| APACHE II score | 21 ± 8 | 22 ± 6 | 0.58 | |||
| MICU | 229 (61%) | 23 (52%) | 0.25 | |||
| Contact rate | 4.6 ± 3.1 | 5.5 ± 3.6 | 0.22 | |||
| Hand hygiene | 47% ± 41% | 53% ± 39% | 0.59 | |||
| Admission diagnoses | ||||||
| Pulmonary disease | 66 (18%) | 15 (34%) | 0.01 | 2.10 | 0.88–5.03 | 0.09 |
| Cardiovascular disease | 24 (6%) | 1 (2%) | 0.27 | |||
| Neurological disease | 62 (17%) | 5 (11%) | 0.37 | |||
| Trauma | 30 (8%) | 14 (32%) | <0.01 | 2.71 | 1.11–6.61 | 0.03 |
| Surgery | 124 (32%) | 6 (14%) | 0.01 | 1.50 | 0.52–4.35 | 0.45 |
| Other | 68 (18%) | 3(7%) | 0.06 | 1.45 | 0.18–11.91 | 0.73 |
| Antibiotic therapy | 237 (63%) | 44 (100%) | <0.01 | |||
| Amoxicillin–clavulanic acid | 127 (34%) | 32 (73%) | <0.01 | 1.49 | 0.70–3.14 | 0.30 |
| Ceftriaxone | 57 (15%) | 8 (18%) | 0.61 | |||
| Aminoglycosides | 71 (19%) | 22 (50%) | <0.01 | 0.97 | 0.50–1.90 | 0.93 |
| Quinolones | 28 (8%) | 5 (11%) | 0.37 | |||